25 XP   0   0   10

Suzhou Zelgen Biopharmaceuticals Co Ltd
Buy, Hold or Sell?

Let's analyse Zelgen together

PenkeI guess you are interested in Suzhou Zelgen Biopharmaceuticals Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Suzhou Zelgen Biopharmaceuticals Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Suzhou Zelgen Biopharmaceuticals Co Ltd

I send you an email if I find something interesting about Suzhou Zelgen Biopharmaceuticals Co Ltd.

Quick analysis of Zelgen (30 sec.)










What can you expect buying and holding a share of Zelgen? (30 sec.)

How much money do you get?

How much money do you get?
¥0.01
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
¥6.61
Expected worth in 1 year
¥9.91
How sure are you?
16.7%

+ What do you gain per year?

Total Gains per Share
¥3.37
Return On Investment
6.1%

For what price can you sell your share?

Current Price per Share
¥55.10
Expected price per share
¥37.29 - ¥55.50
How sure are you?
50%

1. Valuation of Zelgen (5 min.)




Live pricePrice per Share (EOD)

¥55.10

Intrinsic Value Per Share

¥-16.68 - ¥-19.33

Total Value Per Share

¥-10.07 - ¥-12.72

2. Growth of Zelgen (5 min.)




Is Zelgen growing?

Current yearPrevious yearGrowGrow %
How rich?$241.4m$146m$30.3m17.2%

How much money is Zelgen making?

Current yearPrevious yearGrowGrow %
Making money-$10.2m-$18m$7.7m76.3%
Net Profit Margin-83.8%-194.7%--

How much money comes from the company's main activities?

3. Financial Health of Zelgen (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#360 / 1007

Most Revenue
#165 / 1007

Most Profit
#919 / 1007

Most Efficient
#601 / 1007

What can you expect buying and holding a share of Zelgen? (5 min.)

Welcome investor! Zelgen's management wants to use your money to grow the business. In return you get a share of Zelgen.

What can you expect buying and holding a share of Zelgen?

First you should know what it really means to hold a share of Zelgen. And how you can make/lose money.

Speculation

The Price per Share of Zelgen is ¥55.10. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Zelgen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Zelgen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥6.61. Based on the TTM, the Book Value Change Per Share is ¥0.82 per quarter. Based on the YOY, the Book Value Change Per Share is ¥-0.50 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.02 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Zelgen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps-0.05-0.1%-0.04-0.1%-0.07-0.1%-0.05-0.1%-0.05-0.1%
Usd Book Value Change Per Share-0.05-0.1%0.110.2%-0.07-0.1%0.050.1%0.050.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.04-0.1%0.120.2%-0.07-0.1%0.050.1%0.050.1%
Usd Price Per Share6.43-6.36-5.68-6.40-6.40-
Price to Earnings Ratio-35.12--43.65--20.60--35.42--35.42-
Price-to-Total Gains Ratio-144.56--133.66--82.95--150.87--150.87-
Price to Book Ratio7.06-11.39-10.21-9.08-9.08-
Price-to-Total Gains Ratio-144.56--133.66--82.95--150.87--150.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.6038
Number of shares131
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.110.05
Usd Total Gains Per Share0.120.05
Gains per Quarter (131 shares)15.256.77
Gains per Year (131 shares)61.0027.06
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11605112717
2311911215344
3417917328071
45239234210698
572982953133125
683583563159152
7104174174186179
8114774784212206
9125375395239233
10145966005266260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.018.00.00.0%0.018.00.00.0%0.018.00.00.0%
Book Value Change Per Share1.03.00.025.0%1.011.00.08.3%3.015.00.016.7%3.015.00.016.7%3.015.00.016.7%
Dividend per Share4.00.00.0100.0%12.00.00.0100.0%18.00.00.0100.0%18.00.00.0100.0%18.00.00.0100.0%
Total Gains per Share1.03.00.025.0%1.011.00.08.3%3.015.00.016.7%3.015.00.016.7%3.015.00.016.7%

Fundamentals of Zelgen

About Suzhou Zelgen Biopharmaceuticals Co Ltd

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-04-18 18:10:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Suzhou Zelgen Biopharmaceuticals Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Zelgen earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Zelgen to the Biotechnology industry mean.
  • A Net Profit Margin of -141.3% means that ¥-1.41 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The MRQ is -141.3%. The company is making a huge loss. -2
  • The TTM is -83.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-141.3%TTM-83.8%-57.5%
TTM-83.8%YOY-194.7%+110.9%
TTM-83.8%5Y1,484.3%-1,568.1%
5Y1,484.3%10Y1,484.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-141.3%-207.2%+65.9%
TTM-83.8%-216.8%+133.0%
YOY-194.7%-282.4%+87.7%
5Y1,484.3%-434.0%+1,918.3%
10Y1,484.3%-584.8%+2,069.1%
1.1.2. Return on Assets

Shows how efficient Zelgen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Zelgen to the Biotechnology industry mean.
  • -3.1% Return on Assets means that Zelgen generated ¥-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The MRQ is -3.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.1%TTM-3.5%+0.5%
TTM-3.5%YOY-7.8%+4.3%
TTM-3.5%5Y-8.9%+5.4%
5Y-8.9%10Y-8.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.1%-13.2%+10.1%
TTM-3.5%-12.7%+9.2%
YOY-7.8%-11.5%+3.7%
5Y-8.9%-13.8%+4.9%
10Y-8.9%-15.5%+6.6%
1.1.3. Return on Equity

Shows how efficient Zelgen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Zelgen to the Biotechnology industry mean.
  • -5.1% Return on Equity means Zelgen generated ¥-0.05 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The MRQ is -5.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.1%TTM-7.2%+2.1%
TTM-7.2%YOY-12.9%+5.8%
TTM-7.2%5Y-124.1%+116.9%
5Y-124.1%10Y-124.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.1%-16.7%+11.6%
TTM-7.2%-15.9%+8.7%
YOY-12.9%-14.7%+1.8%
5Y-124.1%-19.2%-104.9%
10Y-124.1%-20.0%-104.1%

1.2. Operating Efficiency of Suzhou Zelgen Biopharmaceuticals Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Zelgen is operating .

  • Measures how much profit Zelgen makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Zelgen to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-52.6%+52.6%
TTM-52.6%YOY-212.8%+160.2%
TTM-52.6%5Y2,076.2%-2,128.8%
5Y2,076.2%10Y2,076.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM-52.6%-238.5%+185.9%
YOY-212.8%-291.9%+79.1%
5Y2,076.2%-485.6%+2,561.8%
10Y2,076.2%-610.8%+2,687.0%
1.2.2. Operating Ratio

Measures how efficient Zelgen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.80 means that the operating costs are ¥2.80 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The MRQ is 2.797. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.039. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.797TTM2.039+0.757
TTM2.039YOY3.171-1.132
TTM2.0395Y-18.431+20.470
5Y-18.43110Y-18.4310.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.7973.235-0.438
TTM2.0393.310-1.271
YOY3.1713.791-0.620
5Y-18.4315.675-24.106
10Y-18.4317.558-25.989

1.3. Liquidity of Suzhou Zelgen Biopharmaceuticals Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Zelgen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.38 means the company has ¥2.38 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The MRQ is 2.379. The company is able to pay all its short-term debts. +1
  • The TTM is 2.086. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.379TTM2.086+0.292
TTM2.086YOY2.901-0.815
TTM2.0865Y6.264-4.177
5Y6.26410Y6.2640.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3793.877-1.498
TTM2.0864.178-2.092
YOY2.9015.343-2.442
5Y6.2646.135+0.129
10Y6.2646.468-0.204
1.3.2. Quick Ratio

Measures if Zelgen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Zelgen to the Biotechnology industry mean.
  • A Quick Ratio of 0.37 means the company can pay off ¥0.37 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The MRQ is 0.370. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.534. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.370TTM0.534-0.163
TTM0.534YOY0.283+0.250
TTM0.5345Y1.615-1.081
5Y1.61510Y1.6150.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3703.514-3.144
TTM0.5343.998-3.464
YOY0.2835.380-5.097
5Y1.6156.135-4.520
10Y1.6156.434-4.819

1.4. Solvency of Suzhou Zelgen Biopharmaceuticals Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Zelgen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Zelgen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.39 means that Zelgen assets are financed with 38.8% credit (debt) and the remaining percentage (100% - 38.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The MRQ is 0.388. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.458. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.388TTM0.458-0.070
TTM0.458YOY0.369+0.089
TTM0.4585Y0.344+0.114
5Y0.34410Y0.3440.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3880.339+0.049
TTM0.4580.336+0.122
YOY0.3690.271+0.098
5Y0.3440.368-0.024
10Y0.3440.388-0.044
1.4.2. Debt to Equity Ratio

Measures if Zelgen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Zelgen to the Biotechnology industry mean.
  • A Debt to Equity ratio of 64.1% means that company has ¥0.64 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The MRQ is 0.641. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.920. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.641TTM0.920-0.279
TTM0.920YOY0.629+0.291
TTM0.9205Y4.674-3.754
5Y4.67410Y4.6740.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6410.388+0.253
TTM0.9200.403+0.517
YOY0.6290.340+0.289
5Y4.6740.430+4.244
10Y4.6740.463+4.211

2. Market Valuation of Suzhou Zelgen Biopharmaceuticals Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Zelgen generates.

  • Above 15 is considered overpriced but always compare Zelgen to the Biotechnology industry mean.
  • A PE ratio of -35.12 means the investor is paying ¥-35.12 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The EOD is -41.502. Based on the earnings, the company is expensive. -2
  • The MRQ is -35.122. Based on the earnings, the company is expensive. -2
  • The TTM is -43.654. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-41.502MRQ-35.122-6.380
MRQ-35.122TTM-43.654+8.532
TTM-43.654YOY-20.602-23.051
TTM-43.6545Y-35.421-8.233
5Y-35.42110Y-35.4210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-41.502-2.281-39.221
MRQ-35.122-2.599-32.523
TTM-43.654-2.674-40.980
YOY-20.602-4.133-16.469
5Y-35.421-6.258-29.163
10Y-35.421-6.270-29.151
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The EOD is -34.010. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -28.782. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -36.590. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-34.010MRQ-28.782-5.228
MRQ-28.782TTM-36.590+7.807
TTM-36.590YOY-22.394-14.196
TTM-36.5905Y-29.922-6.668
5Y-29.92210Y-29.9220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-34.010-2.903-31.107
MRQ-28.782-3.323-25.459
TTM-36.590-3.552-33.038
YOY-22.394-5.592-16.802
5Y-29.922-8.378-21.544
10Y-29.922-8.875-21.047
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Zelgen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 7.06 means the investor is paying ¥7.06 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Suzhou Zelgen Biopharmaceuticals Co Ltd:

  • The EOD is 8.337. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.056. Based on the equity, the company is overpriced. -1
  • The TTM is 11.394. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD8.337MRQ7.056+1.282
MRQ7.056TTM11.394-4.339
TTM11.394YOY10.210+1.184
TTM11.3945Y9.077+2.317
5Y9.07710Y9.0770.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.3371.911+6.426
MRQ7.0562.116+4.940
TTM11.3942.097+9.297
YOY10.2102.885+7.325
5Y9.0773.556+5.521
10Y9.0773.959+5.118
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Suzhou Zelgen Biopharmaceuticals Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.3440.825-142%-0.500+45%0.367-194%0.367-194%
Book Value Per Share--6.6094.828+37%3.997+65%4.520+46%4.520+46%
Current Ratio--2.3792.086+14%2.901-18%6.264-62%6.264-62%
Debt To Asset Ratio--0.3880.458-15%0.369+5%0.344+13%0.344+13%
Debt To Equity Ratio--0.6410.920-30%0.629+2%4.674-86%4.674-86%
Dividend Per Share--0.0220.019+15%0.008+169%0.007+206%0.007+206%
Eps---0.332-0.283-15%-0.493+49%-0.362+9%-0.362+9%
Free Cash Flow Per Share---0.405-0.356-12%-0.471+16%-0.379-6%-0.379-6%
Free Cash Flow To Equity Per Share---0.4052.153-119%-0.285-30%0.638-164%0.638-164%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---19.327--------
Intrinsic Value_10Y_min---16.680--------
Intrinsic Value_1Y_max---1.784--------
Intrinsic Value_1Y_min---1.752--------
Intrinsic Value_3Y_max---5.476--------
Intrinsic Value_3Y_min---5.225--------
Intrinsic Value_5Y_max---9.308--------
Intrinsic Value_5Y_min---8.630--------
Market Cap14585410800.000+15%12343342713.18012195763662.870+1%10898028360.000+13%12284805122.860+0%12284805122.860+0%
Net Profit Margin---1.413-0.838-41%-1.947+38%14.843-110%14.843-110%
Operating Margin----0.5260%-2.1280%20.762-100%20.762-100%
Operating Ratio--2.7972.039+37%3.171-12%-18.431+759%-18.431+759%
Pb Ratio8.337+15%7.05611.394-38%10.210-31%9.077-22%9.077-22%
Pe Ratio-41.502-18%-35.122-43.654+24%-20.602-41%-35.421+1%-35.421+1%
Price Per Share55.100+15%46.63046.073+1%41.170+13%46.409+0%46.409+0%
Price To Free Cash Flow Ratio-34.010-18%-28.782-36.590+27%-22.394-22%-29.922+4%-29.922+4%
Price To Total Gains Ratio-170.820-18%-144.562-133.662-8%-82.955-43%-150.868+4%-150.868+4%
Quick Ratio--0.3700.534-31%0.283+31%1.615-77%1.615-77%
Return On Assets---0.031-0.035+15%-0.078+153%-0.089+191%-0.089+191%
Return On Equity---0.051-0.072+41%-0.129+155%-1.241+2346%-1.241+2346%
Total Gains Per Share---0.3230.844-138%-0.492+52%0.374-186%0.374-186%
Usd Book Value--241421924.732176360284.169+37%146008976.173+65%165107351.547+46%165107351.547+46%
Usd Book Value Change Per Share---0.0480.114-142%-0.069+45%0.051-194%0.051-194%
Usd Book Value Per Share--0.9120.666+37%0.552+65%0.624+46%0.624+46%
Usd Dividend Per Share--0.0030.003+15%0.001+169%0.001+206%0.001+206%
Usd Eps---0.046-0.039-15%-0.068+49%-0.050+9%-0.050+9%
Usd Free Cash Flow---14795454.619-12991086.908-12%-17202978.051+16%-13847750.362-6%-13847750.362-6%
Usd Free Cash Flow Per Share---0.056-0.049-12%-0.065+16%-0.052-6%-0.052-6%
Usd Free Cash Flow To Equity Per Share---0.0560.297-119%-0.039-30%0.088-164%0.088-164%
Usd Market Cap2012786690.400+15%1703381294.4191683015385.476+1%1503927913.680+13%1695303106.955+0%1695303106.955+0%
Usd Price Per Share7.604+15%6.4356.358+1%5.681+13%6.404+0%6.404+0%
Usd Profit---12124774.272-10216006.975-16%-18011465.938+49%-13200729.489+9%-13200729.489+9%
Usd Revenue--8580377.72213334836.142-36%9993782.198-14%6151973.582+39%6151973.582+39%
Usd Total Gains Per Share---0.0450.116-138%-0.068+52%0.052-186%0.052-186%
 EOD+5 -3MRQTTM+14 -20YOY+26 -85Y+17 -1810Y+17 -18

3.2. Fundamental Score

Let's check the fundamental score of Suzhou Zelgen Biopharmaceuticals Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-41.502
Price to Book Ratio (EOD)Between0-18.337
Net Profit Margin (MRQ)Greater than0-1.413
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.370
Current Ratio (MRQ)Greater than12.379
Debt to Asset Ratio (MRQ)Less than10.388
Debt to Equity Ratio (MRQ)Less than10.641
Return on Equity (MRQ)Greater than0.15-0.051
Return on Assets (MRQ)Greater than0.05-0.031
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Suzhou Zelgen Biopharmaceuticals Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.517
Ma 20Greater thanMa 5051.039
Ma 50Greater thanMa 10049.234
Ma 100Greater thanMa 20048.720
OpenGreater thanClose54.500
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Interest Income  6,35045,07851,427-45,6815,74614,35420,100-61,607-41,507



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CNY. All numbers in thousands.

Summary
Total Assets2,859,062
Total Liabilities1,109,628
Total Stockholder Equity1,732,140
 As reported
Total Liabilities 1,109,628
Total Stockholder Equity+ 1,732,140
Total Assets = 2,859,062

Assets

Total Assets2,859,062
Total Current Assets2,499,759
Long-term Assets359,303
Total Current Assets
Cash And Cash Equivalents 1,925,597
Short-term Investments 299,440
Net Receivables 89,895
Inventory 114,795
Other Current Assets 4,341
Total Current Assets  (as reported)2,499,759
Total Current Assets  (calculated)2,434,068
+/- 65,691
Long-term Assets
Property Plant Equipment 244,630
Intangible Assets 73,107
Long-term Assets Other 14,167
Long-term Assets  (as reported)359,303
Long-term Assets  (calculated)331,904
+/- 27,399

Liabilities & Shareholders' Equity

Total Current Liabilities1,050,897
Long-term Liabilities58,730
Total Stockholder Equity1,732,140
Total Current Liabilities
Short Long Term Debt 822,686
Accounts payable 117,619
Other Current Liabilities 3,570
Total Current Liabilities  (as reported)1,050,897
Total Current Liabilities  (calculated)943,874
+/- 107,023
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt29,150
Long-term Liabilities  (as reported)58,730
Long-term Liabilities  (calculated)29,150
+/- 29,580
Total Stockholder Equity
Total Stockholder Equity (as reported)1,732,140
Total Stockholder Equity (calculated)0
+/- 1,732,140
Other
Capital Stock264,708
Common Stock Shares Outstanding 264,708
Net Invested Capital 2,554,826
Net Working Capital 1,448,862
Property Plant and Equipment Gross 244,630



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
376,578
296,735
320,268
2,113,204
2,039,161
2,002,288
1,970,282
1,915,774
1,925,466
1,851,625
1,745,962
1,689,373
1,625,314
1,632,983
1,668,311
1,664,960
2,870,961
2,859,062
2,859,0622,870,9611,664,9601,668,3111,632,9831,625,3141,689,3731,745,9621,851,6251,925,4661,915,7741,970,2822,002,2882,039,1612,113,204320,268296,735376,5780
   > Total Current Assets 
0
154,350
116,727
101,824
1,883,297
1,801,498
1,736,775
1,669,568
1,602,463
1,674,158
1,527,202
1,405,956
1,347,854
1,273,809
1,261,492
1,291,755
1,299,980
2,510,460
2,499,759
2,499,7592,510,4601,299,9801,291,7551,261,4921,273,8091,347,8541,405,9561,527,2021,674,1581,602,4631,669,5681,736,7751,801,4981,883,297101,824116,727154,3500
       Cash And Cash Equivalents 
0
88,893
60,799
66,920
1,099,575
1,134,214
1,157,532
1,149,734
1,388,438
1,386,985
1,184,725
1,136,632
1,165,377
1,091,219
784,344
797,047
741,022
1,576,393
1,925,597
1,925,5971,576,393741,022797,047784,3441,091,2191,165,3771,136,6321,184,7251,386,9851,388,4381,149,7341,157,5321,134,2141,099,57566,92060,79988,8930
       Short-term Investments 
0
0
0
6,000
742,000
615,594
509,348
449,850
140,234
110,445
165,311
65,256
15,062
4,009
268,919
248,934
304,184
647,572
299,440
299,440647,572304,184248,934268,9194,00915,06265,256165,311110,445140,234449,850509,348615,594742,0006,000000
       Net Receivables 
0
0
291
7,030
8,055
16,018
24,932
2,620
3,173
82,654
43,930
74,824
20,814
49,492
79,538
88,985
107,517
120,843
89,895
89,895120,843107,51788,98579,53849,49220,81474,82443,93082,6543,1732,62024,93216,0188,0557,03029100
       Other Current Assets 
0
47,000
31,000
15,449
23,764
22,803
25,178
43,834
41,327
54,930
52,411
77,334
82,421
57,633
50,396
45,298
47,882
54,604
4,341
4,34154,60447,88245,29850,39657,63382,42177,33452,41154,93041,32743,83425,17822,80323,76415,44931,00047,0000
   > Long-term Assets 
0
222,228
180,007
218,444
229,908
237,663
265,514
300,714
313,311
251,309
324,423
340,005
341,519
351,505
371,490
376,556
364,980
360,501
359,303
359,303360,501364,980376,556371,490351,505341,519340,005324,423251,309313,311300,714265,514237,663229,908218,444180,007222,2280
       Property Plant Equipment 
0
0
56,331
56,669
57,635
64,695
69,657
91,025
101,936
105,168
174,119
188,911
186,856
210,234
231,028
247,089
244,806
246,136
244,630
244,630246,136244,806247,089231,028210,234186,856188,911174,119105,168101,93691,02569,65764,69557,63556,66956,33100
       Intangible Assets 
0
135,757
103,872
125,428
133,410
114,523
115,540
129,514
123,127
114,933
108,378
116,291
108,733
104,118
99,333
91,030
83,077
78,605
73,107
73,10778,60583,07791,03099,333104,118108,733116,291108,378114,933123,127129,514115,540114,523133,410125,428103,872135,7570
       Other Assets 
0
0
19,803
25,968
38,863
48,190
70,317
70,175
78,248
21,208
31,925
24,804
35,930
27,153
31,129
0
27,096
25,760
0
025,76027,096031,12927,15335,93024,80431,92521,20878,24870,17570,31748,19038,86325,96819,80300
> Total Liabilities 
0
198,265
164,706
246,518
186,191
173,875
215,968
278,692
300,368
409,029
446,064
492,880
575,849
635,986
756,773
880,825
930,570
1,030,379
1,109,628
1,109,6281,030,379930,570880,825756,773635,986575,849492,880446,064409,029300,368278,692215,968173,875186,191246,518164,706198,2650
   > Total Current Liabilities 
0
104,499
107,156
150,168
90,474
81,764
128,325
140,877
163,749
274,497
281,141
380,893
417,961
484,695
611,968
729,186
839,837
948,192
1,050,897
1,050,897948,192839,837729,186611,968484,695417,961380,893281,141274,497163,749140,877128,32581,76490,474150,168107,156104,4990
       Short Long Term Debt 
0
20,000
20,000
60,000
0
0
12,000
17,670
48,107
128,185
112,200
175,391
201,386
228,653
361,226
454,521
621,707
722,504
822,686
822,686722,504621,707454,521361,226228,653201,386175,391112,200128,18548,10717,67012,0000060,00020,00020,0000
       Accounts payable 
0
48,982
50,317
54,033
47,586
47,164
63,933
64,957
69,000
78,853
93,500
118,191
112,442
146,042
147,987
151,721
114,559
119,220
117,619
117,619119,220114,559151,721147,987146,042112,442118,19193,50078,85369,00064,95763,93347,16447,58654,03350,31748,9820
       Other Current Liabilities 
0
0
24,879
19,563
36,081
17,743
40,016
27,326
33,520
29,973
38,425
42,593
75,670
63,930
53,340
59,926
61,271
48,919
3,570
3,57048,91961,27159,92653,34063,93075,67042,59338,42529,97333,52027,32640,01617,74336,08119,56324,87900
   > Long-term Liabilities 
0
93,766
57,551
96,350
95,717
92,111
87,642
137,815
136,619
134,532
164,923
111,987
157,888
151,291
144,805
151,639
90,734
82,187
58,730
58,73082,18790,734151,639144,805151,291157,888111,987164,923134,532136,619137,81587,64292,11195,71796,35057,55193,7660
       Other Liabilities 
0
0
52,799
91,523
90,808
87,931
83,380
103,463
97,765
93,718
68,804
63,811
59,041
55,135
51,179
58,363
0
51,240
0
051,240058,36351,17955,13559,04163,81168,80493,71897,765103,46383,38087,93190,80891,52352,79900
       Deferred Long Term Liability 
0
0
784
866
997
778
2,476
4,351
5,153
7,412
7,019
13,027
13,571
12,673
12,656
20,958
0
18,797
0
018,797020,95812,65612,67313,57113,0277,0197,4125,1534,3512,47677899786678400
> Total Stockholder Equity
0
104,481
59,021
3,426
1,858,759
1,800,269
1,705,021
1,617,725
1,544,464
1,451,952
1,347,664
1,196,323
1,068,822
950,916
843,297
759,118
708,988
1,817,617
1,732,140
1,732,1401,817,617708,988759,118843,297950,9161,068,8221,196,3231,347,6641,451,9521,544,4641,617,7251,705,0211,800,2691,858,7593,42659,021104,4810
   Common Stock
0
0
180,000
180,000
240,000
240,000
240,000
240,000
240,000
240,000
240,000
240,000
240,000
240,000
240,000
240,000
240,000
264,690
0
0264,690240,000240,000240,000240,000240,000240,000240,000240,000240,000240,000240,000240,000240,000180,000180,00000
   Retained Earnings Total Equity0000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
0
1,543
772
1,872
1,813
-1,318
-5,040
-4,523
-5,793
-5,539
-6,325
-6,555
-4,439
-4,132
-2,842
0
-1,173
0
0-1,1730-2,842-4,132-4,439-6,555-6,325-5,539-5,793-4,523-5,040-1,3181,8131,8727721,54300



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue386,517
Cost of Revenue-30,865
Gross Profit355,651355,651
 
Operating Income (+$)
Gross Profit355,651
Operating Expense-721,093
Operating Income-334,576-365,441
 
Operating Expense (+$)
Research Development440,431
Selling General Administrative256,049
Selling And Marketing Expenses-
Operating Expense721,093696,480
 
Net Interest Income (+$)
Interest Income24,274
Interest Expense-20,665
Other Finance Cost-7,369
Net Interest Income10,977
 
Pretax Income (+$)
Operating Income-334,576
Net Interest Income10,977
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-315,276-334,576
EBIT - interestExpense = -20,665
-296,116
-275,451
Interest Expense20,665
Earnings Before Interest and Taxes (EBIT)--294,611
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-315,276
Tax Provision--2,357
Net Income From Continuing Ops-312,919-312,919
Net Income-296,116
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--10,977
 

Technical Analysis of Zelgen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Zelgen. The general trend of Zelgen is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Zelgen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Suzhou Zelgen Biopharmaceuticals Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 55.36 < 55.48 < 55.50.

The bearish price targets are: 45.30 > 42.80 > 37.29.

Tweet this
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current macd is 0.84444961.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Zelgen price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Zelgen. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Zelgen price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartSuzhou Zelgen Biopharmaceuticals Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current adx is 20.88.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Zelgen shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current sar is 46.88.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current rsi is 65.52. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Relative Strength Index (RSI) ChartSuzhou Zelgen Biopharmaceuticals Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Zelgen price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Stochastic Oscillator ChartSuzhou Zelgen Biopharmaceuticals Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current cci is 132.93.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Commodity Channel Index (CCI) ChartSuzhou Zelgen Biopharmaceuticals Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current cmo is 43.48.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Chande Momentum Oscillator (CMO) ChartSuzhou Zelgen Biopharmaceuticals Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current willr is -2.48756219.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Williams %R ChartSuzhou Zelgen Biopharmaceuticals Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Suzhou Zelgen Biopharmaceuticals Co Ltd.

Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current atr is 2.13137591.

Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Average True Range (ATR) ChartSuzhou Zelgen Biopharmaceuticals Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current obv is 83,067,773.

Suzhou Zelgen Biopharmaceuticals Co Ltd Daily On-Balance Volume (OBV) ChartSuzhou Zelgen Biopharmaceuticals Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Suzhou Zelgen Biopharmaceuticals Co Ltd. The current mfi is 62.58.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Money Flow Index (MFI) ChartSuzhou Zelgen Biopharmaceuticals Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Suzhou Zelgen Biopharmaceuticals Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-07ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Suzhou Zelgen Biopharmaceuticals Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Suzhou Zelgen Biopharmaceuticals Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.517
Ma 20Greater thanMa 5051.039
Ma 50Greater thanMa 10049.234
Ma 100Greater thanMa 20048.720
OpenGreater thanClose54.500
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Zelgen with someone you think should read this too:
  • Are you bullish or bearish on Zelgen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Zelgen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Suzhou Zelgen Biopharmaceuticals Co Ltd

I send you an email if I find something interesting about Suzhou Zelgen Biopharmaceuticals Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Suzhou Zelgen Biopharmaceuticals Co Ltd.

Receive notifications about Suzhou Zelgen Biopharmaceuticals Co Ltd in your mailbox!